1.49
-0.03(-1.97%)
Currency In USD
| Previous Close | 1.52 |
| Open | 1.5 |
| Day High | 1.59 |
| Day Low | 1.48 |
| 52-Week High | 5.1 |
| 52-Week Low | 0.99 |
| Volume | 458,328 |
| Average Volume | 1.26M |
| Market Cap | 94.18M |
| PE | -2.61 |
| EPS | -0.57 |
| Moving Average 50 Days | 1.52 |
| Moving Average 200 Days | 2.26 |
| Change | -0.03 |
If you invested $1000 in MacroGenics, Inc. (MGNX) 10 years ago, it would be worth $51.75 as of August 20, 2025 at a share price of $1.49. Whereas If you bought $1000 worth of MacroGenics, Inc. (MGNX) shares 5 years ago, it would be worth $55.29 as of August 20, 2025 at a share price of $1.49.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MacroGenics Appoints Eric Risser as President and Chief Executive Officer
GlobeNewswire Inc.
Aug 13, 2025 8:01 PM GMT
ROCKVILLE, MD, Aug. 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company developing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective as of August
MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement
GlobeNewswire Inc.
Jun 10, 2025 11:00 AM GMT
MacroGenics received $70 million upfront cash payment from Sagard Healthcare Partners (Sagard)MacroGenics’ cash runway extended through first half of 2027 ROCKVILLE, MD, June 10, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clini
MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
GlobeNewswire Inc.
Jun 03, 2025 8:30 PM GMT
ROCKVILLE, MD, June 03, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer,